期刊文献+

P-糖蛋白抑制剂对紫杉醇大鼠体内药动学的影响 被引量:1

The effect of three different P-glycoprotein inhibitors on the pharmacokinetic behaviors of paclitaxel
下载PDF
导出
摘要 目的:比较和分析3种不同P-糖蛋白(P-glycoprotein,P-gp)抑制剂与紫杉醇注射剂(taxol)联合给予大鼠后,P-gp抑制剂对大鼠体内紫杉醇药动学行为的影响。方法:大鼠分别注射给予taxol或联合给予taxol与环孢素A、维拉帕米、槲皮素,采用HPLC测定大鼠体内紫杉醇血浆药物浓度,以3P97软件求算药动学参数。结果:环孢素A和槲皮素均能使紫杉醇大鼠体内的消除行为减缓与生物利用度提高(P<0.05或P<0.01)。维拉帕米的作用较弱(P>0.05)。结论:由于体内的紫杉醇同时受P-gp和CYP3A酶作用,因此具有P-gp和CYP3A酶双重抑制作用的环孢素A和槲皮素可显著改变紫杉醇体内的药动学行为。 OBJECTIVE To compare and analysis the effect of three different P-glycoprotein (P-gp) inhibitors on the pharmaeokinetie behaviors of paelitaxel by intravenous administration to rats. METHODS 24 Rats were divided into 4 groups. One group was given Taxol alone and the other three groups were given Taxol with Cyelosporin A (CsA), verapamil or quereetin, respectively. Plasma concentration of paclitaxel was analyzed by HPLC, and pharraacokinetics parameters were calculated by 3P97. RESULTS CsA, verapamil and quercetin decreased the elimination of paclitaxel and increased the AUC of paclitaxel. CONCLUSION Paelitaxel undergoes the elimination effect of P-gp and CYP3A, the agents that simultaneously inhibit P=gp and CYP3A could significantly increase the bioavailability and decrease the elimination of paelitaxel.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2007年第7期877-880,共4页 Chinese Journal of Hospital Pharmacy
关键词 紫杉醇 药动学 P-糖蛋白 paclitaxel pharrnacokineties P-glycoprotein
  • 相关文献

参考文献10

  • 1Baloglu E, Kingston DG. The taxane diterpenoids [J]. Journal of Natural Products, 1999, 62: 1448-1472. 被引量:1
  • 2E. Marleen Kcmper, A. Erik van Zandbergen, Cindy Cleypool, et al. Increased Penetration of Paclitaxel into the Brain by Inhibition of P-Glycoprotein [J]. Clinical Cancer Research, 2003,9 : 2849-55. 被引量:1
  • 3Rajagopalan Sridhar, Chandradhar Dwivedi, Jayna Anderson, el al. Effects of Veraparnil on the Acute Toxicity of Doxorubitin in vivo[J]. Journal of the National Cancer Institute, 1992, 84:1653-60. 被引量:1
  • 4Bert L. Lum, Sonja Kaubiseh, George A, et al. Effect of high-dose cyclosporine on etoposidc pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance[J]. Cancer Chemotherapy and Pharmacology. 2000, 45:305-311. 被引量:1
  • 5YH Wang, PD Chao, SL Hsiu, et al. Lethal quercetin-digoxin interaction in Digs[J]. Life Science, 2004,74 : 1191-1197. 被引量:1
  • 6Shicheng Yang, R. Neslihan Gursoy, Gregory Lambert, et al. Enhanced Oral Absorption of Paclitaxel in a NovelSelf-Microemulsifying Drug Delivery System with or withoul Concomitant Use of P-Glycoprotein Inhibitors[J]. Pharmaceutical Research, 2004,21:261-270. 被引量:1
  • 7苏成业.P-糖蛋白在药物代谢动力学中的作用及其临床意义[J].药学学报,2005,40(8):673-679. 被引量:23
  • 8Jun-Shik Choi, Byung-Wok Jo, Youn-Chul Kim, et al. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rals pretreated with quercetin[J]. European Journal of Pharmaceutics and Biopharmaeeuties, 2004, 57:313-318. 被引量:1
  • 9Ping Gao, Bohhy D. Rush, William P. Pfund, et al. Development of a Supersaturable SEDDS (S-SEDDS) Formulation of Paclitaxel with Improved Oral Bioavailability[J]. Journal of Pharmaceutical Science, 2003,92:2386-2398. 被引量:1
  • 10Jun-Shik Choia, Xiuguo Lia. The effect of verapamil on the pharmacokineues of paclitaxel in rats[J]. European Journal of Pharmaceutical Sciences, 2005,24:95-100. 被引量:1

二级参考文献21

  • 1Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein) : recent advances andclinical relevance[ J ]. Clin Pharmacol Ther, 2004,75(1):13-33. 被引量:1
  • 2Zhang Y, Benet LZ. The gut as a barrier to drug absorption : combined role of cytochrome P450 3A and P-glycoprotein[ J ]. Clin Pharmacokinet, 2001,40 ( 3 ) :159 - 168. 被引量:1
  • 3Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications [ J ]. Clin Pharmacokinet, 2003,42( 1 ) :59 -98. 被引量:1
  • 4Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical,cellular, and pharmacological aspects of the multidrug transporter[J]. Annu Rev Pharmacol Toxicol, 1999,39 :361 - 398. 被引量:1
  • 5Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter [ J ].Annu Rev Pharmacol Toxicol , 2003,43:285 - 307. 被引量:1
  • 6Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development[J]. Pharmacol Rev, 2003,55(3):425 -461. 被引量:1
  • 7Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes [ J ]. Annu Rev Pharmacol Toxicol , 2001,41:535 - 567. 被引量:1
  • 8Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications[ J ]. Clin Pharmacokinet, 2004,43 ( 9 ) :553 - 576. 被引量:1
  • 9Yamazaki M, Neway WE, Ohe T, et al. In vitro substrate identification studies for p-glycoprotein mediated transport: species difference and predictability of in vitro results [ J ]. J Pharmacol Exp Ther, 2001,296 ( 3 ) :723 - 735. 被引量:1
  • 10Hall SD. Molecular and physical mechanisms of first-pass extraction [J]. Drug Metab Dispos, 1999,27(2) :161 -166. 被引量:1

共引文献22

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部